{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"180"}],"title":"CLL/SLL"},{"measurements":[{"groupId":"OG000","value":"16"}],"title":"Other NHL"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Treatment discontinuation"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"199"}],"units":"Participants"}],"description":"Investigator-assessed responses were summarized descriptively for subjects with CLL/SLL and listed for subjects with other NHLs based on the efficacy population.","groups":[{"description":"This was a multicenter, open-label, monotherapy, long-term extension study designed to evaluate the long-term (\\> 6 months) safety and tolerability of a fixed daily dosing regimen of ibrutinib. PCI-32765: Dose based on parent protocol CLL: chronic lymphocytic leukemia/ SLL: small lymphocytic lymphoma.","id":"OG000","title":"IBRUTINIB/PCI-32765"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"30 days after last dose of study drug, continue up to 6 months","title":"Documented Responses","type":"SECONDARY","unitOfMeasure":"Participants"}